Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RHONE-POULENC BEGINS TENDER OFFER FOR RORER; DEAL SET TO CLOSE BY END OF JUNE

Executive Summary

Rhone-Poulenc began a $78 a share tender offer for one-half of Rorer's outstanding shares on March 16. The two companies announced a definitive merger agreement earlier in the week on March 12. Following completion of the merger, Rhone-Poulenc will own 68% of the new company, Rhone-Poulenc Rorer, Inc. The new entity combines the pharmaceutical operations of the French firm with the Rorer operation and does not include other Rhone-Poulenc Health Sector businesses, such as vaccines, animal health and nutrition and Rhone's interest in Roussel Uclaf. The definitive deal puts a value of about $73 on each share of Rorer stock, according to the two companies. Rorer and Rhone-Poulenc earlier had agreed on that price in an agreement-in-principle to merge, announced Jan. 18 ("The Pink Sheet" Jan. 22, p. 3). Following the offer, which is based on a minimum of 32.4 mil. Rorer shares being tendered, Rhone-Poulenc will transfer its worldwide human pharmaceutical assets and issue contingent value rights (CVRs) equal to the remaining number of outstanding Rorer common stock held by Rorer shareholders. Rorer will assume approximately $265 mil. in Rhone-Poulenc debt, purchase the firm's U.S. drug business for $20 mil. and issue to Rhone-Poulenc about 24 mil. Rorer shares to bring the French firm's ownership in Rorer up to about 68%, according to a March 12 release. Rorer will then distribute the CVRs to its other shareholders, with each CVR entitling the holder to receive from Rhone-Poulenc, at the maturity date, an amount by which the target price of $98.26 exceeds the greater of the average market value of the Rorer common shares prior to the maturity date or a floor price of $52. Rhone-Poulenc is, in effect, offering current shareholders$78 per share now for half of their shares and guaranteed rights to $98.26 per share in three years. The CVRs also will be traded separately, adding to the investment interest. The full price for the deal calculates out to just over $3 bil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel